Cargando…

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS

Detalles Bibliográficos
Autores principales:	Garcia-Manero, Guillermo, Matsuno, Rayna K., Mcbride, Ali, Makinde, Adeola Y, Brown, Thomas D., Idryo, Danny, Broome, Ronda, Herriman, Autumn, Wilkinson, Kristiana, Walters, Sheetal, Schrag, Andrew, Mohammed, Hina, Izano, Monika A., Mukherjee, Sudipto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429899/ http://dx.doi.org/10.1097/01.HS9.0000974880.20066.a9

Ejemplares similares

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS
por: Huang, Yumin, et al.
Publicado: (2018)

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
por: Elvarsdóttir, Edda María, et al.
Publicado: (2019)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
por: Raimbault, Anna, et al.
Publicado: (2016)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
por: Gonçalves, Ana Cristina, et al.
Publicado: (2021)

Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia
por: Parisi, Sarah, et al.
Publicado: (2021)

Discontinuation of the renin–angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes
por: Pavlidis, George, et al.
Publicado: (2021)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome
por: Rujirachaivej, Punchita, et al.
Publicado: (2018)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1 mutated myelodysplasia
por: Mian, Syed A, et al.
Publicado: (2023)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
por: Lazo-Langner, Alejandro, et al.
Publicado: (2019)

SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast
por: Carrocci, Tucker J., et al.
Publicado: (2017)

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
por: Choudhary, Gaurav S, et al.
Publicado: (2022)

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
por: Ma, Liya, et al.
Publicado: (2022)

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome
por: Garelius, H. K. G., et al.
Publicado: (2016)

The Preston Retreat
Publicado: (1889)

Networking erythropoiesis
por: Kerenyi, Marc A., et al.
Publicado: (2010)

Fracture Resistance of Retreated Roots Using Different Retreatment Systems
por: Er, Kursat, et al.
Publicado: (2011)

Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand
por: Yimpak, Phuttirak, et al.
Publicado: (2019)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome
por: Ochi, Tetsuro, et al.
Publicado: (2022)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Retreats : handmade hideaways to refresh the spirit
por: Drinkard, G. Lawson, 1951-
Publicado: (1997)

Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes
por: Patel, Jay L., et al.
Publicado: (2020)

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2023)

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
por: Aslaner Ak, Müzeyyen, et al.
Publicado: (2023)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes
por: Lieu, Yen K., et al.
Publicado: (2021)

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process
por: Jiang, Moqin, et al.
Publicado: (2023)

Retreat for Intemperate Women
Publicado: (1863)

Retreat for Intemperate Women
Publicado: (1863)

Winter Retreat for Consumptives
Publicado: (1867)

Cannot write session to /tmp/vufind_sessions/sess_4o5t1d3uib1vtu7fv5lbhi0fe7